TARO Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	26 688.00
Vidutinė apimtis	43 979.00
Rinkos kapitalizacija	1.59B
EPS	$0 ( 2024-01-25 )
Kita pelno data	( $0.310 ) 2024-05-28
Last Dividend	$12.81 ( 2018-12-10 )
Next Dividend	$0 ( N/A )
P/E	34.75
ATR14	$0.0200 (0.05%)

Insider Trading

Date	Person	Action	Amount	type
2011-01-18	Sun Pharmaceutical Industries Ltd	Buy	712 500	Restricted Shares
2011-01-18	Sun Pharmaceutical Industries Ltd	Buy	712 500	Restricted Shares
2011-01-18	Sun Pharmaceutical Industries Ltd	Sell	712 500	Warrant (right to buy)
2010-11-04	Sun Pharmaceutical Industries Ltd	Buy	5 159 765	Ordinary Shares
2010-11-01	Franklin Resources Inc	Sell	5 159 765	Ordinary Shares

INSIDER POWER
0.00
Last 84 transactions
Buy: 16 575 249 \| Sell: 25 681 902

Tūris Koreliacija

Ilgas: 0.07 (neutral)

Trumpas: -0.73 (moderate negative)

Signal:(41.437) Neutral

Taro Pharmaceutical Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Taro Pharmaceutical Koreliacija - Valiuta/Žaliavos

0.69
( moderate )

0.88
( strong )

0.00
( neutral )

0.49
( neutral )

0.18
( neutral )

0.84
( strong )

Taro Pharmaceutical Finansinės ataskaitos

Annual	2023
Pajamos:	$572.95M
Bruto pelnas:	$268.32M (46.83 %)
EPS:	$0.680

FY	2023
Pajamos:	$572.95M
Bruto pelnas:	$268.32M (46.83 %)
EPS:	$0.680

FY	2022
Pajamos:	$561.35M
Bruto pelnas:	$293.12M (52.22 %)
EPS:	$1.550

FY	2021
Pajamos:	$548.97M
Bruto pelnas:	$296.66M (54.04 %)
EPS:	$-10.12

Financial Reports:

No articles found.

Taro Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Taro Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 5.86 - average (62.51%) | Divividend Growth Potential Score: 2.19 - No dividend growth expected in the near future

Information

First Dividend	$12.81	2018-12-10
Last Dividend	$12.81	2018-12-10
Next Dividend	$0	N/A
Payout Date	2018-12-28
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$12.81	--
Avg. Dividend % Per Year	0.00%	--
Score	1.22	--
Div. Sustainability Score	5.86
Div.Growth Potential Score	2.19
Div. Directional Score	4.03	--

Next Divdend (Est)
(2024-04-29)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

1.22

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2018	$12.81	12.40%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0748	1.500	8.50	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0211	1.200	9.30	10.00	[0 - 0.3]
returnOnEquityTTM	0.0261	1.500	-0.821	-1.231	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.60	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.03	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.022	1.500	5.43	8.15	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	-2.55	1.000	-2.05	-2.05	[3 - 30]
operatingCashFlowPerShareTTM	3.80	2.00	8.73	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.29	2.00	8.86	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.480	1.000	5.33	5.33	[0.2 - 0.8]
operatingProfitMarginTTM	0.0360	1.000	-1.280	-1.280	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.282	0.800	-1.451	-1.161	[0.5 - 2]
Total Score				5.86

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	34.87	1.000	6.58	0	[1 - 100]
returnOnEquityTTM	0.0261	2.50	-0.528	-1.231	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.29	2.00	9.24	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	3.80	2.00	8.73	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.769	1.500	-8.46	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.234	1.000	6.65	0	[0.1 - 0.5]
Total Score				2.19

Taro Pharmaceutical

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.